Sun Pharmaceutical Intrinsic Value
Sun Pharmaceutical intrinsic value. Sun Pharmaceutical (SUNPHARMA) median intrinsic value is ₹3516.00 from 10 valuation models (range ₹527–₹4395), vs current price ₹1758.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with SUNPHARMA fundamental valuation to assess whether the stock is under or overvalued.
SUNPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Sun Pharmaceutical intrinsic value across 10 models vs current price ₹1758.00 — upside/downside and value range per method. For current market price and key ratios, visit SUNPHARMA stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹994.40 | ₹795.52 - ₹1193.28 | -43.4% | EPS: ₹45.20, Sector P/E: 22x |
| Book Value Method | asset | ₹4395.00 | ₹3955.50 - ₹4834.50 | +150.0% | Book Value/Share: ₹3495.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3516.00 | ₹3164.40 - ₹3867.60 | +100.0% | Revenue/Share: ₹2503.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3516.00 | ₹3164.40 - ₹3867.60 | +100.0% | EBITDA: ₹17444.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4395.00 | ₹3516.00 - ₹5274.00 | +150.0% | CF Growth: 8.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹527.40 | ₹474.66 - ₹580.14 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹698.34 | ₹628.51 - ₹768.17 | -60.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3516.00 | ₹3164.40 - ₹3867.60 | +100.0% | ROE: 12.9%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1885.32 | ₹1696.79 - ₹2073.85 | +7.2% | EPS: ₹45.20, BVPS: ₹3495.00 |
| Dividend Yield Method | dividend | ₹640.00 | ₹576.00 - ₹704.00 | -63.6% | DPS: ₹16.00, Target Yield: 2.5% |
SUNPHARMA Intrinsic Value vs Market Price — All Valuation Models
Sun Pharmaceutical fair value range ₹527–₹4395 vs current market price ₹1758.00 across 10 valuation models. Read SUNPHARMA dividend payout details for the complete payout history and dividend yield track record.
SUNPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Sun Pharmaceutical median intrinsic value ₹3516.00, current price ₹1758.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of SUNPHARMA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Sun Pharmaceutical (SUNPHARMA) is ₹3516.00 (median value). With the current market price of ₹1758.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹527.40 to ₹4395.00, indicating ₹527.40 - ₹4395.00.
Is SUNPHARMA undervalued or overvalued?
Based on our multi-method analysis, Sun Pharmaceutical (SUNPHARMA) appears to be trading below calculated value by approximately 100.0%.
SUNPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Sun Pharmaceutical financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 12.9% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUNPHARMA Cash Flow Quality — Operating & Free Cash Flow
Sun Pharmaceutical operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹12,419 Cr | ₹7,217 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹14,072 Cr | ₹11,481 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹12,135 Cr | ₹11,754 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹4,959 Cr | ₹1,349 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹8,985 Cr | ₹6,207 Cr | Positive Free Cash Flow | 8/10 |